Clinical trialNCT02922764CompletedPhase 1Interventional

A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer

SponsorInspirna, Inc.Enrollment146Endometrial CancerEndometrial Cancer RecurrentLung CancerLung Cancer RecurrentNon-small Cell CarcinomaNon-small Cell Lung Cancer Metastatic

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Study RGX-104-001 is a Phase 1, first-in-human, dose escalation and expansion study of RGX-104, an oral small molecule targeting the liver X receptor (LXR), as a single agent and in combination with nivolumab, ipilimumab, docetaxel, or pembrolizumab plus carboplatin/pemetrexed.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Robert Wasserman, MD
Inspirna, Inc.
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

21 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Arizona Oncology
Tucson, Arizona, United States
Cedars-Sinai Medical Center
Los Angeles, California, United States
University of Colorado
Aurora, Colorado, United States
Rocky Mountain Cancer Centers
Denver, Colorado, United States
Sarah Cannon Research Institute
Denver, Colorado, United States
Florida Cancer Specialist
Lake Mary, Florida, United States
Comprehensive Hematology Oncology
St. Petersburg, Florida, United States
James Graham Brown Cancer Center
Louisville, Kentucky, United States
Ochsner Clinic Foundation
New Orleans, Louisiana, United States
Maryland Oncology
Columbia, Maryland, United States
Regions Hospital
Saint Paul, Minnesota, United States
Dartmouth Hitchcock Medical
Lebanon, New Hampshire, United States
Cinj
New Brunswick, New Jersey, United States
Quantum Santa Fe
Santa Fe, New Mexico, United States
Columbia University Medical Center
New York, New York, United States
Ou Health Stephenson Cancer Center
Oklahoma City, Oklahoma, United States
Oregon Health Sciences University
Portland, Oregon, United States
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, United States
the Sarah Cannon Research Institute
Nashville, Tennessee, United States
Virginia Cancer Specialists, Pc
Fairfax, Virginia, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Carboplatin →Docetaxel →Ipilimumab →Pembrolizumab →Pemetrexed →RGX-104

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 1 Nov 2016
Primary completion: 22 Jan 2025
Completion: 22 Jan 2025
Last update posted: 26 Mar 2025
Registered enrollment: 146
Registry id: NCT02922764

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.